Sri Lanka Registration Fees in USD and LKR, Updated Monthly

Updated: 2026-11-11 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

Sri Lanka’s device fee mechanism differs markedly from other markets: fees are denominated in US dollars, converted into rupees at the selling rate published by the Central Bank of Sri Lanka (CBSL) on the last working day of the previous month, and the fee schedule is issued monthly. Taking the April 2026 fee schedule as an example, the conversion rate was the dollar selling rate of 319.312 rupees on 2026-03-31. A new application from a foreign applicant of 1,000 US dollars corresponds to 319,312 rupees, to which are added 18% VAT (58,913.06 rupees) and 2.5% SSCL (7,982.80 rupees), for a total of 386,207.86 rupees. Every rupee figure therefore carries a month attribute, and quoting one without its month and rate is meaningless for budgeting.

  • Fees are denominated in US dollars, not in rupees.
  • Conversion uses the CBSL selling rate published on the last working day of the previous month.
  • The fee schedule is published monthly, so rupee amounts change with the exchange rate.
  • April 2026 schedule: selling rate 319.312 rupees per dollar (2026-03-31); foreign new application 1,000 USD = 319,312 rupees.
  • VAT at 18% and SSCL at 2.5% are added on top of the converted amount.
  • Total for the foreign new application: 386,207.86 rupees, roughly 21% above the dollar nominal amount.

2. Legal basis

The mechanism is defined in the NMRA monthly fee schedules for medical devices and in the official procedural explanations on the NMRA website. The table below reproduces the elements of the mechanism, including the specific figures published in the April 2026 schedule.

ItemContentSource
Pricing currencyFees are denominated in US dollarsNMRA medical device monthly fee schedule
Conversion ruleConverted to rupees at the CBSL selling rate published on the last working day of the previous monthSame source
Publication frequencyPublished monthlyNMRA official procedural explanation
Conversion rate, April 2026 scheduleDollar selling rate 319.312 rupees (2026-03-31)April 2026 fee schedule
Foreign new application1,000 US dollars → 319,312 rupees, total 386,207.86 rupeesSame source
VAT18%Same source
SSCL2.5%Same source
Stamp dutyListed in the schedule as — (not charged)Same source

The practical consequence of this design is that budgeting must always be three-dimensional: the dollar amount, the applicable month, and the conversion rate of that month. A rupee figure quoted without its month cannot be verified, repeated, or defended in an audit, because the rate underneath it changes every month. For multi-year programmes the same logic extends forward: since the dollar amounts are the stable anchor, plan the programme in dollars and treat each rupee figure as a snapshot that will be refreshed by the schedule in force when payment falls due. This keeps budgets comparable across markets and across years, and it avoids locking a client into a rupee number that the next monthly schedule may already have superseded.

3. Expert insights

Insight one: every rupee amount carries a month attribute. Because the rate is adjusted monthly, quoting a rupee amount out of its monthly context is meaningless. We write all quotations and budgets uniformly as the dollar amount, the applicable month, and the conversion rate of that month. This discipline keeps internal approvals, client budgets, and payment requests aligned on the same set of numbers, and it makes any later variance immediately traceable to the rate rather than to an error.

Insight two: the fee is tied to the application type. The authority states explicitly that the amount payable depends on the application type (site registration or product registration) and on the information the local agent provides in the online form. This means the accuracy of the form directly affects the amount payable. The April 2026 schedule demonstrates the arithmetic end to end: a foreign new application of 1,000 US dollars converts at 319.312 rupees per dollar to 319,312 rupees, then carries VAT of 58,913.06 rupees and SSCL of 7,982.80 rupees to reach 386,207.86 rupees. Working through one schedule line by line in this way is the fastest way to internalise the mechanism before applying it to an entire portfolio.

Insight three: VAT and SSCL are layered on top of the converted dollar amount. Taking 1,000 US dollars as the example, the amount is first converted to 319,312 rupees, then 18% VAT and 2.5% SSCL are applied, for a total of roughly 386,208 rupees — actual outlay about 21% above the nominal dollar amount. Budgets built only on the dollar figures will systematically understate the cash requirement by about a fifth, which is exactly the kind of gap that surfaces mid-project when payment falls due.

4. Practical recommendations

  • Use a fee template with five columns: fee item → dollar amount → applicable month → current CBSL selling rate → converted rupee total (including VAT and SSCL).
  • State on every quotation that the official fee schedule of the month of submission prevails, so the boundary of responsibility for exchange-rate movement is clear from the start.
  • Download the NMRA medical device monthly fee schedule for the month of submission before quoting, and archive it with the budget for later verification.
  • Reconcile the online form entries against the fee line before payment, since the fee depends on the application type and the information provided by the local agent.
  • Confirm the payment location is the NMRA Accounts Division.
  • Carry the stamp duty line as shown in the current schedule rather than assuming any amount, since the schedule lists it as — for the period shown.

5. Verification checklist

  • □ The NMRA medical device monthly fee schedule for the month of submission has been downloaded
  • □ The current CBSL dollar selling rate has been checked
  • □ Rupee amounts have been calculated item by item (including 18% VAT and 2.5% SSCL)
  • □ The applicable month has been stated on the quotation
  • □ The payment location has been confirmed as the NMRA Accounts Division

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across South Asia, including Sri Lanka. Our team prepares dossiers to NMRA expectations, manages submissions and deficiency responses, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com

Regulatory information verified as of 28 October 2026.

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail